PRESS RELEASE published on 12/12/2024 at 21:30, 1 year 10 months ago Inside Information / Other news releases Medincell joins Euronext SBF 120 & CAC Mid 60 indices, enhancing visibility and investor appeal. Market capitalization-based indices by Euronext. Effective inclusion from Dec 20 Market Capitalization Medincell Index Inclusion Euronext SBF 120 CAC Mid 60
BRIEF published on 11/28/2024 at 18:45, 1 year 11 months ago Medincell Announces Video Conference for Half-Year Results Half-year Results Schizophrenia Medincell Videoconference BEPO Technology
BRIEF published on 11/22/2024 at 18:05, 1 year 11 months ago MedinCell: Update of share capital and voting rights Share Capital Voting Rights Euronext Actions Medincell
BRIEF published on 11/06/2024 at 13:47, 1 year 11 months ago Medincell: 2024 revenues on the rise and significant clinical progress Clinical Trial Revenue Projections Medincell Olanzapine LAI UZEDY
PRESS RELEASE published on 11/06/2024 at 13:42, 1 year 11 months ago Inside Information / Other news releases Medincell achieves 25% increase in 2024 UZEDY® revenue outlook reaching $100M and key milestone in Olanzapine LAI Phase 3 clinical trials. Teva Pharmaceuticals shares Q3 results Revenue Clinical Trials Medincell Teva Pharmaceuticals UZEDY
BRIEF published on 10/01/2024 at 15:47, 2 years ago Threshold crossing by Mirova in MEDINCELL Capital Actions Threshold Crossing Medincell Mirova
BRIEF published on 09/24/2024 at 11:54, 2 years 1 month ago Teva and Medincell Present Promising Results on Olanzapine LAI for Schizophrenia Clinical Trial Schizophrenia Medincell Teva Olanzapine LAI
PRESS RELEASE published on 09/24/2024 at 11:53, 2 years 1 month ago Inside Information / Other news releases Teva and Medincell reveal positive efficacy, safety, and tolerability data from Phase 3 study on Olanzapine LAI for schizophrenia treatment, presenting at ECNP 2024 Schizophrenia Treatment Phase 3 Study Medincell Teva Olanzapine LAI
BRIEF published on 09/18/2024 at 10:13, 2 years 1 month ago Mirova crosses the threshold of 5% of voting rights in MEDINCELL Voting Rights Actions Threshold Crossing Medincell Mirova
BRIEF published on 09/11/2024 at 07:35, 2 years 1 month ago Medincell establishes a new liquidity contract with Rothschild Martin Maurel Common Shares Euronext Paris Liquidity Contract Rothschild Martin Maurel Medincell
Published on 10/30/2026 at 23:35, 1 day 4 hours ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 1 day 4 hours ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 1 day 8 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 1 day 12 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 10/31/2026 at 16:35, 11 hours 1 minute ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 1 day 4 hours ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 18:38, 1 day 8 hours ago EQS-Adhoc: Starcom Holding AD publishes Interim Q3 2026 Financial Report
Published on 10/30/2026 at 23:00, 1 day 4 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 12:00, 1 day 15 hours ago Capital increase through exercise of subscription rights
